Monte Rosa Therapeutics, Inc. (GLUE) Research

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Market snapshot

Symbol
GLUE
Price
$18.31
Day change
-0.54%
Market cap
$1.2B
P/E ratio
-9.84x
52-week range
4.12-25.77
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$35.00

Peer companies

  • Arvinas, Inc. (ARVN)
  • ArriVent BioPharma, Inc. Common Stock (AVBP)
  • Day One Biopharmaceuticals, Inc. (DAWN)
  • Ginkgo Bioworks Holdings, Inc. (DNA)
  • Geron Corporation (GERN)
  • MeiraGTx Holdings plc (MGTX)
  • Replimune Group, Inc. (REPL)
  • Theravance Biopharma, Inc. (TBPH)

Recent insider activity

  • Champoux Jennifer — M-Exempt (2176 shares) on 2026-06-17
  • Champoux Jennifer — S-Sale (2176 shares) on 2026-06-17
  • Champoux Jennifer — M-Exempt (2176 shares) on 2026-06-17
  • Townson Sharon — M-Exempt (3000 shares) on 2026-06-17
  • Townson Sharon — M-Exempt (3000 shares) on 2026-06-17

Open Monte Rosa Therapeutics, Inc. (GLUE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.